Scientists at Duke University found that the drug ceftobiprole, an antibiotic used to fight bacterial pneumonia, is also effective in treating resistant Staphylococcus aureus. The research was published in the journal NEJM.
Doctors tested the two antibiotics on 390 patients with complicated staphylococcal infections in 17 countries between 2018 and 2022. About half of them were randomly assigned to receive ceftobiprole instillation. The other half was treated with the antibiotic daptomycin, which has been shown to be effective against resistant Staphylococcus aureus.
Ceftobiprole has been shown to be effective against methicillin-resistant staphylococcus (MRSA) infections. Overall improvement was observed in 69.8% of patients in the ceftobiprole group and 68.7% in the daptomycin group. The result means that ceftobiprole is noninferior to daptomycin. The most common side effect of both drugs was gastrointestinal problems. Ceftobiprole may be another option in fighting life-threatening bacterial infection
“Despite all the efforts of scientists, the survival rate for complex staphylococcal infections is still only 75%. Not a single new antibiotic has been approved to treat the infection in over 15 years. S. aureus“, noted the authors.
previous doctors warned About the dangers of frequent consumption of sushi due to the presence of superbugs in them.
Source: Gazeta
Barbara Dickson is a seasoned writer for “Social Bites”. She keeps readers informed on the latest news and trends, providing in-depth coverage and analysis on a variety of topics.